Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1980 Nov;43(11):1012–1015. doi: 10.1136/jnnp.43.11.1012

Abnormal regulation of prolactin release in idiopathic Parkinson's disease.

N F Lawton, J MacDermot
PMCID: PMC490753  PMID: 6777462

Abstract

Levodopa with carbidopa suppressed prolactin release induced by thyrotrophin releasing hormone less effectively in patients with idiopathic Parkinson's disease than in normal subjects. This finding supports the view that the biochemical defect in idiopathic Parkinson's disease extends to the hypothalamus and is not confined to the basal ganglia. Aetiological considerations in Parkinson's disease should encompass a widespread disorder of neurotransmission whose extent merits further investigation.

Full text

PDF
1012

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown G. M., Garfinkel P. E., Warsh J. J., Stancer H. C. Effect of carbidopa on prolactin, growth hormone and cortisol secretion in man. J Clin Endocrinol Metab. 1976 Jul;43(1):236–239. doi: 10.1210/jcem-43-1-236. [DOI] [PubMed] [Google Scholar]
  2. Friesen H., Guyda H., Hwang P., Tyson J. E., Barbeau A. Functional evaluation of prolactin secretion: a guide to therapy. J Clin Invest. 1972 Mar;51(3):706–709. doi: 10.1172/JCI106859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hornykiewicz O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br Med Bull. 1973 May;29(2):172–178. doi: 10.1093/oxfordjournals.bmb.a070990. [DOI] [PubMed] [Google Scholar]
  4. Lloyd K., Hornykiewicz O. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science. 1970 Dec 11;170(3963):1212–1213. doi: 10.1126/science.170.3963.1212. [DOI] [PubMed] [Google Scholar]
  5. Malarkey W. B., Jacobs L. S., Daughaday W. H. Levodopa suppression of prolactin in nonpuerperal galactorrhea. N Engl J Med. 1971 Nov 18;285(21):1160–1163. doi: 10.1056/NEJM197111182852102. [DOI] [PubMed] [Google Scholar]
  6. Refetoff S., Fang V. S., Rapoport B., Friesen H. G. Interrelationships in the regulation of TSH and prolactin secretion in man: effects of L-dopa, TRH and thyroid hormone in various combinations. J Clin Endocrinol Metab. 1974 Mar;38(3):450–457. doi: 10.1210/jcem-38-3-450. [DOI] [PubMed] [Google Scholar]
  7. Rinne U. K. Recent advances in the treatment of Parkinsonism with drugs. Acta Neurol Scand Suppl. 1972;51:59–103. [PubMed] [Google Scholar]
  8. Sinha Y. N., Selby F. W., Lewis U. J., VanderLaan W. P. A homologous radioimmunoassay for human prolactin. J Clin Endocrinol Metab. 1973 Mar;36(3):509–516. doi: 10.1210/jcem-36-3-509. [DOI] [PubMed] [Google Scholar]
  9. Takahara J., Arimura A., Schally A. V. Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. Endocrinology. 1974 Aug;95(2):462–465. doi: 10.1210/endo-95-2-462. [DOI] [PubMed] [Google Scholar]
  10. Thorner M. O. Dopamine is an important neurotransmitter in the autonomic nervous system. Lancet. 1975 Mar 22;1(7908):662–665. doi: 10.1016/s0140-6736(75)91762-6. [DOI] [PubMed] [Google Scholar]
  11. Thorner M. O., McNeilly A. S., Hagan C., Besser G. M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J. 1974 May 25;2(5916):419–422. doi: 10.1136/bmj.2.5916.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Woolf P. D., Leebaw W. J., Lee L. A. Effects of CNS dopamine augmentation on stimulated prolactin secretion. J Clin Endocrinol Metab. 1977 Oct;45(4):857–860. doi: 10.1210/jcem-45-4-857. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES